Onderneming Brainstorm Cell Therapeutics Inc. Deutsche Boerse AG
Aandelen
GHDN
US10501E2019
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,511 EUR | +9,07% | +2,61% | +122,17% |
Vakgebied
Aantal werknemers: 29
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chaim Lebovits
CEO | Chief Executive Officer | 53 | 01-07-07 |
Alla Patlis
DFI | Director of Finance/CFO | 37 | 23-12-12 |
Chief Tech/Sci/R&D Officer | - | 12-05-22 | |
Bob Dagher
CTO | Chief Tech/Sci/R&D Officer | 55 | 17-07-23 |
Yael Gothelf
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-07 |
Stacy Lindborg
BRD | Director/Board Member | 53 | 01-06-20 |
Uri Yablonka
BRD | Director/Board Member | 47 | 06-06-14 |
General Counsel | - | 12-05-22 | |
Mary Kay Turner
LAW | General Counsel | - | 07-08-17 |
Yossef Levy
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Irit Arbel
FOU | Founder | 64 | 22-09-00 |
Uri Yablonka
BRD | Director/Board Member | 47 | 06-06-14 |
Jacob Frenkel
CHM | Chairman | 81 | 30-03-20 |
Director/Board Member | 63 | 28-10-21 | |
Director/Board Member | 61 | 05-02-18 | |
Stacy Lindborg
BRD | Director/Board Member | 53 | 01-06-20 |
Nir Naor
BRD | Director/Board Member | 50 | 20-06-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 70 080 523 | 60 766 674 ( 86,71 %) | 0 | 86,71 % |
Bedrijfsgegevens
Brainstorm Cell Therapeutics, Inc.
1325 Avenue of Americas 28th floor
10019, New York
+201 488 0460
http://www.brainstorm-cell.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+43,38% | 54,04 mld. | |
+43,57% | 41,96 mld. | |
-1,21% | 41,92 mld. | |
-7,59% | 28,35 mld. | |
+11,90% | 26,35 mld. | |
-21,90% | 19 mld. | |
+7,75% | 13 mld. | |
+29,16% | 12,28 mld. | |
+25,52% | 12,19 mld. |
- Beurs
- Aandelen
- Koers BCLI
- Koers GHDN
- Onderneming Brainstorm Cell Therapeutics Inc.